Evidence map›Paper›PMID 31183807›Full record

ReviewMolecular neurobiology2019

Addressing Alzheimer's Disease (AD) Neuropathology Using Anti-microRNA (AM) Strategies.

Vivian R Jaber, Yuhai Zhao, Nathan M Sharfman, Wenhong Li, Walter J Lukiw

Open access · greenAbstract readReview
In one paragraph

Review in Molecular neurobiology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 30 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
30citing papers in PubMed, 1 pooled it
1.9field-weighted citation impact, top 15% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

30 citing papers in PubMed, 1 synthesis or guideline pooled it, 38 citations in OpenAlex.

  1. Pooled it
  2. Review
  3. Article
  4. Review
  5. Review
  6. Article
  7. Review
  8. Review
  9. Article
  10. Review
  11. Review
  12. Article
  13. MicroRNA29B induces fetal hemoglobinFrontiers in medicine · 2022
    Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. microRNA-146a-5p, Neurotropic Viral Infection and Prion Disease (PrD).International journal of molecular sciences · 2021
    Review
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 2 institutions in 2 countries.

Vivian R JaberLSU Neuroscience Center, Louisiana State University Health Sciences Center, New Orleans, LA, 70112, USA.
Yuhai ZhaoLSU Neuroscience Center, Louisiana State University Health Sciences Center, New Orleans, LA, 70112, USA.
Nathan M SharfmanLSU Neuroscience Center, Louisiana State University Health Sciences Center, New Orleans, LA, 70112, USA.
Wenhong LiLSU Neuroscience Center, Louisiana State University Health Sciences Center, New Orleans, LA, 70112, USA.
Walter J LukiwLSU Neuroscience Center, Louisiana State University Health Sciences Center, New Orleans, LA, 70112, USA. wlukiw@lsuhsc.edu.ORCID http://orcid.org/0000-0001-5500-4402
Louisiana State University Health Sciences Center New Orleans · USJiangxi University of Traditional Chinese Medicine · CN

Funding

OCULAR HSV: LATENCY, REACTIVATION, &RECURRENCER01EY006311 · NEI · LSU HEALTH SCIENCES CENTER · PI HILL, JAMES M · 1985 to 2012
$5.3M
microRNA (miRNA) signaling in Alzheimer's disease(AD)R01AG038834 · NIA · LSU HEALTH SCIENCES CENTER · PI BAZAN, NICOLAS G. · 2011 to 2020
$3.3M
Gene Expression in Alzheimer's DiseaseR01AG018031 · NIA · LSU HEALTH SCIENCES CENTER · PI LUKIW, WALTER J · 2001 to 2006
$1.4M
LSU Eye Center from Research to Prevent Blindness RPBNational Institute of Aging NIA AG18031 and NIA AG038834NEI NIH HHS R01 EY006311NIA NIH HHS R01 AG018031NIA NIH HHS R01 AG038834
6 · The paper itself

Abstract

Disruptions in multiple neurobiological pathways and neuromolecular processes have been widely implicated in the etiopathology of Alzheimer's disease (AD), a complex, progressive, and ultimately lethal neurological disorder whose current incidence, both domestically and globally, is reaching epidemic proportions. While only a few percent of all AD cases appear to have a strong genetic or familial component, the major form of this disease, known as idiopathic or sporadic AD, displays a multi-factorial pathology and represents one of the most complex and perplexing neurological disorders known. More effective and innovative pharmacological strategies for the successful intervention and management of AD might be expected: (i) to arise from strategic-treatments that simultaneously address multiple interrelated AD targets that are directed at the initiation, development, and/or propagation of this disease and (ii) those that target the "neuropathological core" of the AD process at early or upstream stages of AD. This "Perspectives paper" will review current research involving microRNA (miRNA)-mediated, messenger RNA (mRNA)-targeted gene expression pathways in sporadic AD and address the potential implementation of evolving anti-microRNA (AM) strategies in the amelioration and clinical management of AD. This novel-therapeutic approach: (i) incorporates a system involving the restoration of multiple miRNA-regulated mRNA-targets via the use of selectively-stabilized AM species; and (ii) that via implementation of synthetic AMs, the abundance of only relatively small-families of miRNAs need be modulated or neutralized to re-establish neural-homeostasis in the AD-affected brain. In doing so, these strategic approaches will jointly and interactively address multiple AD-associated processes such as the disruption of synaptic communication, defects in amyloid peptide clearance and amyloidogenesis, tau pathology, deficits in neurotrophic support, alterations in the innate immune response, and the proliferation of neuroinflammatory signaling.

Indexed as

Alzheimer DiseaseAnimalsBrainGene TargetingGenetic VectorsHumansMicroRNAsNervous System DiseasesMicroRNAsAlzheimer’s diseasemessenger RNA (mRNA)microRNA (miRNA)miRNA-125bmiRNA-146amiRNA-155miRNA-34amiRNA-7miRNA-9miRNA-mRNA linkage analysis

Identifiers

PMID31183807
PMCPMC6842093
OpenAlexW2950670670

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.